Peptide library › Cancer & imaging
Lutetium Lu-177 dotatate
Also known as Lutathera, 177Lu-DOTATATE, PRRT
Targeted radiation therapy that delivers radiation straight to neuroendocrine tumours.
What people use it for
- Somatostatin receptor-positive gut and pancreatic neuroendocrine tumours
What Lutetium Lu-177 dotatate does in the body
A somatostatin-like peptide carrying radioactive lutetium-177. It homes in on tumour cells that carry somatostatin receptors and irradiates them from close range.
Strength of evidence
Strong: the NETTER-1 trial greatly delayed tumour growth.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Nausea and vomiting
- Low blood counts
- Kidney effects, so a protective amino acid infusion is given
- Rare later blood cancers
Who should avoid it or take extra care
- Pregnancy or breastfeeding, unless a specialist advises it
- Severe kidney impairment
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved in 2018 for adults, later extended to adolescents. Given in specialist nuclear medicine centres.
How it's taken
Route: Four infusions into a vein, about 8 weeks apart
How long it lasts (half-life): Lutetium-177 loses half its radioactivity every 6.7 days
Storage
Stored and prepared by the pharmacy or clinic, following the product label.
Latest research & news
- Radiopharmaceuticals for Melanoma Theranostics
Research · Study · PubMed · Methods Mol Biol · 21 Nov 2026 - Neuroendocrine Theranostics
Research · Review · PubMed · Magn Reson Imaging Clin N Am · 21 Nov 2026 - 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Clinical trial · Not yet recruiting · Phase 1/2 · Updated · ClinicalTrials.gov · 20 Nov 2026 - Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Clinical trial · Recruiting · Phase 1/2 · Updated · ClinicalTrials.gov · 20 Nov 2026 - Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
Clinical trial · Not yet recruiting · Updated · ClinicalTrials.gov · 20 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Lutetium Lu-177 dotatate privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Lutetium Lu-177 dotatate in Fiala How to installMore in Cancer & imaging
- DegarelixMonthly hormone-blocking injection for advanced prostate cancer that lowers testosterone fast, without an initial flare.
- Lutetium Lu-177 vipivotide tetraxetanTargeted radiation therapy for advanced prostate cancer that carries the PSMA protein.
- Gallium Ga-68 dotatateRadioactive tracer used in PET scans to find neuroendocrine tumours.
- MotixafortideInjection that releases stem cells from the bone marrow so they can be collected before a transplant for multiple myeloma.
- BalixafortideExperimental CXCR4 blocker studied with chemotherapy for advanced breast cancer; its Phase 3 trial failed.
- LTX-315Experimental cancer-killing peptide injected directly into tumours to trigger an immune response.